Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2019. The document serves as a transaction notification regarding a specific corporate action involving the company's Performance Share Plan.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a single transaction involving the acquisition of Ordinary Shares:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares following the re-investment of dividends paid on January 10, 2019.
- Volume: 1,994.395 shares.
- Price: £15.3600 per share.
- Location: London Stock Exchange (XLON).
- Restrictions: Shares are subject to a 2-year holding period.
Material Changes
The filing does not provide comparative financial data or material changes to the company's overall financial position versus prior periods. The only reported change is the specific increase in share holdings by the Chief Financial Officer via dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically Mr. S Dingemans, Chief Financial Officer.
Investor Verification Points
- Verify the impact of the dividend reinvestment on the total outstanding share count (negligible given the volume).
- Confirm the 2-year holding period restriction on the 1,994.395 shares acquired by the CFO.
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.